Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months. - Trial 2014-004543-12

Name: Clinical Trial 2014-004543-12
Creator: Novartis Vaccines and Diagnostics Srl.
Keywords: Influenza, clinical trial

Access comprehensive clinical trial information for 2014-004543-12 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Vaccines and Diagnostics Srl. and is currently status unknown. The study focuses on Influenza.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database

840K+ Trials

2014-004543-12

Trial Details

EU Clinical Trials Register • 2014-004543-12

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months.

Study Focus

Disease/Condition

Influenza

Sponsor & Location

Primary Sponsor

Novartis Vaccines and Diagnostics Srl.

Timeline & Enrollment

Phase

N/A

Start Date

N/A

End Date

N/A

Primary Outcome

• Number and percentage of children with at least one local or systemic reaction between 1 and 7 days after any vaccine injection.

ICD-10 Classifications

Influenza and pneumonia

Influenza due to identified seasonal influenza virus

Influenza with other manifestations, seasonal influenza virus identified

Influenza with pneumonia, seasonal influenza virus identified

Influenza due to identified zoonotic or pandemic influenza virus

Data Source

Registry

EU Clinical Trials Register

Trial ID

2014-004543-12

Type

Non-Device Trial